- Scrip Originals
- Featured Topics
Athena Neurosciences Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Athena Neurosciences Inc.
Prothena views potential approval of Biogen’s aducanumab as a flag in the sand for next-generation amyloid-targeting therapies to race past, including the firm’s own antibody and vaccine programs.